Novo Nordisk announced its CagriSema GLP-1 weight loss drug underperformed Eli Lilly's tirzepatide in a trial. Separately, Lilly announced patients can use a single injector to hold a month's supply ...

The Eli Lilly logo appears on a laptop computer screen in this photo illustration in Athens, Greece, on February 9, 2026. Vaccine manufacturers play a central role in global public health, investing ...

Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash. Eli Lilly on Monday said Orna, which is dedicated to engineering immune ...

Matthew Herper covers medical innovation — both its promise and its perils. Eli Lilly will pay up to $2.4 billion to acquire Orna Therapeutics, a biotechnology firm that is developing a technology to ...

As the 2026 Winter Olympics get underway in Italy this week, Eli Lilly—a partner of both Team USA and the Milan Cortina Games as a whole—is rolling out a new corporate campaign inspired by the event.

Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ...

Profit and revenue forecasts for 2026 well above Street view Lilly's Q4 profit and revenue exceed expectations Lilly's obesity drug Zepbound boosts sales despite price cuts Lilly's orforglipron pill ...

Eli Lilly said it will spend $3.5 billion to build a manufacturing plant in Pennsylvania's Lehigh Valley that will help make its next-generation obesity drugs. That includes a closely watched ...

Global pharmaceutical firm Eli Lilly and Co. will invest $3.5 billion to build a manufacturing plant in Upper Macungie Township that is expected to create 850 jobs. “This is the largest single project ...

Forbes contributors publish independent expert analyses and insights. Anisha Sircar is a journalist covering tech, finance and society. This voice experience is generated by AI. Learn more. This voice ...

Eli Lilly LLY0.72%increase; green up pointing triangle and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop an oral treatment for obesity ...